Market Research Report
Asia Pacific Multiplex Assay Market Forecast 2019-2027
|Asia Pacific Multiplex Assay Market Forecast 2019-2027|
Published: March 12, 2019
Content info: 79 Pages
Delivery time: 2-3 business days
The Asia Pacific market for the multiplex assay is predicted to exhibit a CAGR of 10.28% during the projected period of 2019-2027. The market growth in the overpopulated region is driven by the increasing research and development activities, growing demand for healthcare facilities, rise in healthcare reforms, and technological advancements.
The market of the multiplex assay in the Asian Pacific region is separated into regions of South Korea, Australia, China, Japan, India, and the rest of Asia Pacific for further analysis. There is a steady growth in the South Korean market due to an increase in the demand for quality healthcare, demand for molecular testing and point-of-care testing , and efforts by the government to increase the use of these products by promoting medical tourism, implementing u-healthcare and regulating multiplex assay. In Australia, the emerging use of the multiplex assay in IVD is garnering attention. The treatments which allow multiplex assay are cost effective as they are specific. They are critical in the use of cancer drugs in Australia. The rest of Asia Pacific includes countries such as Indonesia, South Korea, Philippines, Malaysia, Thailand, Singapore, Vietnam, and others. The market in these regions are mainly propelled by the growing focus of the government in research and development of precision medicine for liver cancer.
Merck Millipore, Meso Scale Diagnostics LLC, Olink Proteomics AB, Qiagen, Randox Laboratories Ltd, Randox Laboratories Ltd, Siemens Healthineers, Thermo Fisher, etc. are some of the key players in the market.